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Abstract： Nivolumab is one of most used monoclonal antibody for  advanced non-small cell lung 26 
cancer treatment;  presence of its anti-antibody is considered a negative prognostic factor. Vitamin 27 
D (VD) modulates  expression of genes involved in drug metabolism/elimination and immune 28 
system regulation and its deficiency is frequent in these patients. To date no data have been 29 
reported about nivolumab and VD relationship. Aim of this study was to quantify plasma 25-30 
hydroxyVD (25-VD) and 1,25-VD, nivolumab and its anti-antibody before starting treatment (baseline) and 31 
at 15, 45 and 60 days of therapy.VD-pathway associated gene single nucleotide polymorphisms (SNPs) were 32 
also evaluated. Molecules were quantified through enzyme-linked immunosorbent assay, SNPs through real-33 
time PCR. Forty-five patients are enrolled: median nivolumab concentrations were 12.5ug/mL, 22.3ug/mL 34 
and 27.1ug/mL at 15, 45 and 60 days respectively. No anti-nivolumab antibodies were found. Correlations 35 
were observed between nivolumab concentrations and 25-VD levels. Nivolumab concentrations were 36 
affected by VD-pathway related gene SNPs. VDBP AC/CC genotype and baseline 25-VD <10 ng/mL 37 
predicted nivolumab concentrations <18.7ug/mL cut-off value at 15 days, associated with tumor 38 
progression. This is the first study showing VD markers predictors of nivolumab concentrations in real-life 39 
context of non-small cell lung cancer treatment. 40 
Keywords: monoclonal antibody; NSCLC; immune-therapy; ELISA; pharmacokinetics; 41 
pharmacogenetics 42 
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  44 
1. Introduction 45 
Immunotherapy represents most revolutionary treatment for solid cancers nowadays. To date, 46 
several types of immunotherapy are available, including monoclonal antibodies, non-specific 47 
immunotherapies, oncolytic virus therapy, T-cell therapy and cancer vaccines. The evolution of 48 
immune checkpoint inhibitors, as anticancer treatment options, represents one of the most 49 
successful approach in cancer drug research in the past few years[1]. Check point inhibitors 50 
antibodies, such as anti- programmed cell death protein 1 (PD-1) and its ligand (PD-L1), are new 51 
drugs acting as tumor suppressing factor, since they are able to modulate the interaction between 52 
immune cell and tumor cell[2]. These therapies proved to be safe and effective option in advanced 53 
non-small cell lung cancer (NSCLC) and can be recommended selectively[3].  54 
Nivolumab, a monoclonal antibody, binds to the immune-modulating PD-1, blocking ligand 55 
interaction and downstream signaling pathways. The result is a positive regulation of T-cell 56 
function resulting in an antitumor effect[4]. In 2015 this drug was approved by FDA for treatment 57 
of patients with advanced squamous and non-squamous NSCLC with progression or after 58 
platinum-based chemotherapy (second-line therapy)[5]. In a randomized trial 272 patients treated 59 
with nivolumab had an overall survival of 3.2 months longer than those on docetaxel[2]. 60 
In a conference abstract, authors measured nivolumab plasma concentrations in patients and 61 
suggested that partial responders had higher nivolumab mean trough concentrations (27.4 ug/mL) 62 
compared to subjects with tumor progression (18.7 ug/mL)[6]. 63 
PD-1 inhibitors typically cause fewer and less severe treatment-related adverse events (AEs) 64 
compared with conventional chemotherapy compounds, although immune-related AEs can occur 65 
requiring monitoring and specialized management to prevent serious complications[7]. Moreover, 66 
immunogenicity, in terms of presence of nivolumab’s anti-antibodies, is considered a negative  67 
prognostic factor[8]. Immunogenicity and immune checkpoints in general are regulated by different 68 
factors such as vitamin D (VD)[9]: reported studies show that VD controls different pathways 69 
related to innate and adaptive immunity regulating the expression of many genes involved in drug 70 
metabolism/elimination through its receptor (VDR). Moreover, in another study, single nucleotide 71 
polymorphisms (SNPs) in genes involved in VD pathway could affect VD kinetics and, 72 
consequently, its action. Polymorphisms present near genes involved in cholesterol production, 73 
hydroxylation, and VD transport are able to predict who could have risk of VD insufficiency, as 74 
suggested by Wang et al. [10]. Genetic variations near DHCR7 (4p12 (overall p=1.9x10(-109) for 75 
rs2282679, in GC); 11q12 (p=2.1x10(-27) for rs12785878), near CYP2R1 (11p15 (p=3.3x10(-20) for 76 
rs10741657) and near CYP24A1 (20q13) are genome-wide significant in that population. 77 
Furthermore, participants with a score obtained combining the three variants in the highest quartile 78 
are at increased risk of 25-VD levels lower than 75 nmol/L or than 50 nmol/L, compared with those 79 
in the lowest quartile. 80 
Since VD deficiency is frequent in lung cancer patients[11] and no data on nivolumab and its 81 
relationship with VD are currently available, aim of this study was to quantify 25-hydroxyVD (25-82 
VD), 1,25-hydroxyVD (1,25-VD), nivolumab and its anti-antibody levels in patients’ plasma at 83 
different timings, also considering their influence in predicting the cut-off value (18.7 ug/mL), 84 
associated with tumor progression. 85 
2. Results  86 
2.1 Patients characteristics  87 
Baseline (BL) characteristics for  45 included patients are reported in Table 1. Thirty-one  (69) 88 
were male, age was 73 years and  body mass index (BMI) was 23.4 Kg/m2. 89 
 90 
 91 
 92 
 93 
 94 
Table 1. Baseline characteristics of  study population 95 
Characteristics n (%), median (IQR) 
n 45 
Age (years) 73 (65-79.5) 
Male sex 31 (69) 
BMI (Kg/m2) 23.4 (20.1-26.4) 
Caucasian 45 (100) 
 
 
NSCLC type 
Adenocarcinoma                                              34 (52.3) 
Squamous cell carcinoma                                 9 (13.8) 
Poorly differentiated carcinoma                        1 (1.5) 
Large-cell neuroendocrine carcinoma              1 (1.5) 
Concomitant drugs 
Cardiovascular                                                  24 (36.9) 
Diabetes                                                                 4 (6.2) 
Opioids                                                                 9 (13.8) 
Protease inhibitors                                           20 (30.8) 
Corticosteroid                                                   12 (18.5) 
Vitamin D                                                               2 (3.1) 
Pre-treatment drugs 
Cisplatine                                                           24 (53.3) 
Docetaxel                                                           10 (22.2) 
Carboplatine                                                      24 (53.3) 
Gemcitabine                                                      12 (26.7) 
Gefitinib                                                                  2 (4.4) 
Pemetrexed                                                       30 (66.7) 
Afatinib                                                                   1 (2.2) 
Osimertinib                                                            1 (2.2) 
Erlotinib                                                             20 (44.4) 
Vinorelbine                                                        10 (22.2) 
Paclitaxel                                                                3 (6.7) 
Bevacizumab                                                          3 (6.7) 
Etoposide                                                               4 (8.9) 
Zoledronic acid                                                                   1 (2.2) 
Bavicizumab                                                           1 (2.2) 
Farletuzumab                                                        1 (2.2) 
Radiotherapy                                                         1 (2.2) 
 96 
2.2. Nivolumab and vitamin D concentrations  97 
Median nivolumab concentrations were 12.5 ug/mL (9.5-17.1 ug/mL), 22.3 ug/mL (IQR:18.30-98 
34.88 ug/mL) and 27.1 ug/mL (IQR:17.4-39.4 ug/mL) respectively at 15, 45 and 60 days (figure 1). No 99 
anti-nivolumab antibodies were detected.  100 
 101 
Figure 1. Nivolumab plasma concentrations at  15, 45 and 60 days. 102 
25-VD  concentration was 12.8 ng/mL (10.1-16.6 ng/mL), 13.6 ng/mL (10.9-16.1 ng/mL), 11.8 103 
ng/mL (10.1-18.9 ng/mL) and 12.9 ng/mL (10.8-17.0 ng/mL) at BL, 15, 45 and 60 days respectively.  104 
1,25-VD  value was 33.7 pg/mL (23.4-40.6 ng/mL), 34.7 ng/mL (22.3-45.4 ng/mL), 28.5 ng/mL 105 
(20.7-41.5 ng/mL) and 35.7 ng/mL (IQR:19.2-49.0 ng/mL) respectively at BL, 15, 45 and 60 days.  106 
Correlations (figure 2) were observed between nivolumab concentrations at 15 days and BL 25-107 
VD levels (p=0.024, Pearson’s coefficient (PC) 0.451) and at 15 days (p=0.017, PC=0.542); nivolumab 108 
exposure at 60 days was correlated with 25-VD at BL (p=0.001, PC=0.730), at 15 (p<0.001, PC=0.858), 109 
45 (p=0.001, PC=0.779) and 60 days (p<0.001, PC=0.900). Furthermore, in a sub-group, patients were 110 
stratified according to 25-VD deficiency: BL 25-VD levels < 10 ng/mL were associated with lower 111 
nivolumab concentrations at 15 (p=0.103, a trend without statistical significance), 45 (p=0.018) and 60 112 
days (p=0.021); 15 days 25-VD < 10 ng/mL with 15 (p=0.019), 45 (p=0.019) and 60 days (p=0.028) 113 
nivolumab lower concentrations; finally, 60 days 25-VD < 10 ng/mL with 60 days lower nivolumab 114 
levels (p=0.030). No correlation was observed for 1,25-VD and nivolumab exposure. 115 
 116 
 117 
Figure 2. Nivolumab and 25-hydroxyvitamin D correlations at different timings. 118 
2.3. Pharmacogenetics 119 
Variant genotype frequencies (%) were calculated  and reported in Table 2. 120 
Table 2. Variant allele frequencies. 121 
SNP 
% HOMOZIGOUS 
WILD TYPE 
% 
HETEROZYGOUS 
% HOMOZYGOUS 
MUTANT 
CYP27B1 +2838 C>T 20 CC 2.2 CT 77.8 TT 
CYP27B1 -1260 G>T 73.3 CC 15.6 CT 11.1 TT 
CYP24A1 rs2248359 T>C 42.2 TT 40 TC 17.8 CC 
CYP24A1 rs927650 C>T 33.3 CC 22.2 CT 44.5 TT 
CYP24A1 rs2585428 A>G 31.1 AA 28.9 AC 40 CC 
VDR Cdx2 A>G 17.8 AA 13.3 AG 68.9 GG 
VDR TaqI T>C 33.3 TT 26.7 TC 40 CC 
VDR FokI T>C 11.1 TT 42.2 TC 46.7 CC 
VDR BsmI G>A 42.2 GG 57.8 GA - 
VDR ApaI C>A 26.7 CC 28.9 CA 44.4 AA 
VDBP rs7041 T>G 6.7 TT 62.2 TG 31.1 GG 
No genetic variants showed to affect VD concentrations.  122 
Nivolumab plasma concentrations at 15 days (figure 3) were associated with VDR TaqI CC 123 
(p=0.042), ApaI CA/AA (p=0.030) and CYP27B1-1260 TT (p=0.014). Nivolumab exposure at 45 days 124 
(figure 4) were influenced by VDR Cdx2 AG/GG (p=0.019), VDBP rs7041 AC/CC (p=0.035) and 125 
CYP27B1-1260 TT (p=0.028); nivolumab exposure at 60 days (figure 5) was affected by VDR Cdx2 126 
AG/GG (p=0.022) and TaqI TC/CC (p=0.021).  127 
 128 
Figure 3. Gene variants’ influence on nivolumab plasma concentrations at 15 days. 129 
 130 
Figure 4. Gene variants’ influence on nivolumab plasma concentrations at 45 days. 131 
 132 
Figure 5. Gene variants’ influence on nivolumab plasma concentrations at 60 days. 133 
2.4. Regression analysis 134 
Logistic regression analysis was performed to evaluate factors (demographic, clinical, 135 
pharmacological or genetic ones) were able to predict nivolumab concentrations < 18.7 ug/mL at 15 136 
days (table 3). According to Bonferroni test, p<0.003 was considered the adjusted p-value, but no 137 
factors reached this value in univariate analysis. In a multivariate model, VDBP (GC) AC/CC 138 
genotype and BL 25-VD resulted predictors of this cut-off value, associated with tumor progression 139 
(figure 6). 140 
Table 3. Logistic regression analyses: factors able to predict nivolumab concentrations < 18.7 ug/mL 141 
at 15 days of therapy. Bold represents statistically significant values. NC: all the factors belong to a 142 
single group, thus statistics could show p-values and OR. 143 
 144 
 
NIVOLUMAB CONCENTRATIONS ≤ 18.7 ug/mL 
   UNIVARIATE MULTIVARIATE 
   p VALUE OR (95% IC) p VALUE OR (95% IC) 
BMI < 25 Kg/m2  0.766  1.270 (0.392-6.112)  
  Age > 60 years  0.939  0.970 (0.091-9.145)  
  Gender (male) 0.213  2.260 (0.692-12.419)  
  DRUG DOSAGE < 200 mg  0.945  1.056 (0.099-4.867)  
  VDBP (GC) AC/CC 0.059  11.667 (0.909-149.700)  0.049  10.667 (0.830-137.145)  
CYP24A1 3999 CC  NC  
   VDR TaqI TC/CC  0.164  3.077 (0.632-14.976)  
  CYP27B1 -1260  GG  0.148  3.250 (0.658-16.040)  
  PRE 25-HYDROXYVITAMIN D  NC  
 
NC  
 PRE 1,25-HYDROXYVITAMIN D  0.124  3.840 (0.692-21.312)  
  Adenocarcinoma NSCLC type  NC  
   Squamous cell carcinoma                                  NC
   Cisplatine pre-treatment  0.093  4.442 (0.852-24.853) 
  Carboplatine pre-treatment 0.190 0.300 (0.051-1.854) 
  Pemetrexed pre-treatment NC  
    145 
 146 
Figure 6. VDBP rs7041 SNP and pre-25 hydroxyvitamin D levels predictors of the nivolumab cut-off 147 
value of 18.7 ug/mL at 15 days, associated with tumor progression. 148 
3. Discussion  149 
Nivolumab represents an active treatment strategy with the potential of long-term disease 150 
control[12]. Unfortunately, reliable efficacy biomarkers are lacking, thus nivolumab has not been 151 
considered to be cost-effective in several national health systems[13],[14]. 152 
However, a meta-analysis[3] about immune checkpoint inhibitors and chemotherapy in the 153 
treatment of advanced NSCLC, showed significant advantages in terms of overall survival, 154 
progression free survival and overall response rate, compared with conventional chemotherapy in 155 
patients with advanced disease. 156 
VD is able to regulate the immune system. Its synthesis begins by action of the ultraviolet light 157 
in the contest of skin tissue; cholecalciferol is hydroxylated to calcifediol (25-VD) in liver through 158 
cytochrome P-450 (CYP, 27A1, 2R1); in kidney calcitriol (1,25-VD, the active form) is synthesized 159 
through CYP27B1 and  transported in bloodstream through vitamin D binding protein (VDBP). 160 
Inactivation of 25-VD to calcitroic acid (24,25-VD) is carried on by CYP24A1. VD deficiency is 161 
frequently observed in cancer patients: Bochen et al. suggested that VD serum levels were 162 
significantly lower in head and neck cancer patients compared to controls, particularly in patients 163 
with lymphatic metastasis[15]. Different studies show that lower 25-VD serum level is associated 164 
with several negative outcomes in lung cancer. Feng et al. analyzed seventeen studies in a meta-165 
analysis:  statistically significant relationship between 25-VD and lung cancer risk and mortality, 166 
but not with overall lung cancer survival were observed. In addition, they suggested differences 167 
between male and female and in Caucasian and Asian, in terms of cancer risk.  168 
In the current study, 25-VD influences nivolumab concentrations, but not 1,25-VD. Here, we 169 
only evaluate nivolumab and VD concentrations and not the effect on the immune cells: VD 170 
deficiency could have a relapse in terms of immune system, which is directly related to this 171 
treatment. In fact, in another study, and not in the current, a relationship between immune cells and 172 
25-VD and not with 1,25-VD exists, as shown for regulatory T cell function in multiple sclerosis 173 
affected patients[16]. The information about the VD influence on immune system lacks in this study 174 
and this limitation will be the aim of further studies, as considered by our group. 175 
Furthermore, 1,25-VD is present with a concentration 1000 times lower than 25-VD in blood: 176 
such low 1,25-VD concentrations could be more difficult to measure compared to 25-VD levels. 177 
Finally, absence of statistical significance could be due to the small sample size.  178 
Furthermore, in the current study, nivolumab plasma levels in real-life context of NSCLC were 179 
described at different timings and, in addition, the role of 25-VD concentrations and VDBP rs7041 180 
A>C SNP in predicting concentrations lower than 18.7 ug/mL (cut-off value associated with tumor 181 
progression as shown by Stijn et al.[6])  is suggested. 182 
Various VDBP genetic variants are known; the two most common polymorphisms, 1296 A>C 183 
(rs7041, Glu432Asp) and 1307 C>A (rs4588, Thr436Lys) are localized in exon 11 and they are in 184 
complete linkage disequilibrium[17]. Circulating VDBP seems to be not influenced by rs7041 SNP, 185 
however, considering 1296/1307 diplotype, there is a slight transport increase in AC/CA, compared 186 
to AA/CA. Probably, lysine to threonine substitution at position 436 eliminates an O-glycosylation 187 
site from the molecule and the loss of glycosylation influences VDBP half-life. Moreover, glutamine 188 
to asparagine change in 432 position, affects the extent of O-glycosylation at the 436. It is not known 189 
how changes in VDBP molecule modify its serum concentration, but the described substitutions 190 
could result in altered rates of transcription, changes in mRNA stability or in a self-clearance of the 191 
protein[18]. In a recent study on Caucasian women, AA genotype was related to higher breast 192 
cancer risk, compared to healthy controls[19].  193 
Controversial studies are present in literature concerning VDBP rs7041 influence on VD levels: 194 
Lafi et al. show that genotypes containing the variant allele of rs7041 (TT, TG) are associated with 195 
lower 25-VD concentrations than the GG genotype, whereas Daffara et al. did not find an 196 
association in coronary heart disease affected patients and suggest that 25-VD levels, but not VDBP 197 
genetic status, independently predicted the presence of coronary lesions at angiography[20, 21]. 198 
Also in the current study, an association between VDBP genetic variant and VD levels has been 199 
evidenced, although a border-line influence (p=0.049) is present with nivolumab cut-off value, but 200 
the best predictor factor remains 25-VD < 10 ng/mL, as showed in the regression. It is important to 201 
understand which is the relationship: is the VD associated with poorer outcome or it could be an 202 
underlying condition? In our opinion, VD deficiency could be able to affect the outcome, since it is 203 
involved in the regulation of the immune system; furthermore, in deficient individuals before 204 
starting therapy, the situation could be more difficult to manage and complications could be more 205 
severe (for example concerning cachexia).     206 
Schmid et al. showed immunotherapy efficacy was dependent on the metastatic location[22]. 207 
For these reasons, it is very important to understand which biomarkers could predict patients with 208 
higher probability to have tumor progression. 209 
Our study would recommend to clinicians to evaluate 25-VD levels and VDBP rs7041 210 
genotype, before starting therapy, and to quantify nivolumab concentrations at 15 days, to 211 
eventually consider a drug dosage modification or VD supplementing, reducing the risk of tumor 212 
progression. It is important to highlight that these analyses are preliminary and have several 213 
limitations: they are conducted on few individuals (only 45 patients), only one cohort is analyzed 214 
and VDBP SNP has a border-line influence (p=0.049).  215 
4. Materials and methods 216 
Patients treated with nivolumab affected by advanced NSCLC treated within the Italian 217 
Nivolumab Expanded Access Program (NCT02475382) and enrolled in a mono-institutional 218 
translational research study at the Lung Cancer Unit of the Ospedale San Martino (Genova, Italy) 219 
approved by the Local Ethics Committee (registry number: P.R. 191REG2015).  Patients were 220 
eligible if they met the following criteria: i) cytologically or histologically confirmed 221 
advanced/metastatic NSCLC, ii) progression after at least one line of platinum-based 222 
chemotherapy, iii) Eastern Cooperative Oncology Group Performance Status (ECOG-PS)= 0-2, iv) no 223 
previous treatment with immune checkpoint inhibitors, iv) any brain metastasis had to be treated 224 
and clinically stable for at least 14 days before starting nivolumab, v) no treatment with 225 
corticosteroids at a dose higher than 10 mg/day of prednisone or equivalent. Eligible patients 226 
receive nivolumab at 3 mg/kg every 14 days, with assessment by computed tomography scan (CT-227 
scan) every 8 weeks. Nivolumab was administered until onset of unacceptable toxicities, patient's 228 
refusal, death or up to 96 weeks from the start of treatment; treatment beyond tumor progression 229 
was allowed based on Investigators' judgment as long as clinical benefit is perceived.  230 
Values of 25-VD and 1,25-VD were evaluated at BL and at 15, 45 and 60 days after starting 231 
therapy, with enzyme linked immunosorbent assay technique (DRG DIAGNOSTIC, Marburg, 232 
Germany) and with LIAISON®  XL (DiaSorin, Saluggia, Italy), respectively. Nivolumab and its anti-233 
antibody are quantified with  validated  ELISA kits (Matrix Biotek, Ankara, Turkey). 234 
Whole blood was withdrawn in EDTA tubes, genomic DNA was isolated from blood samples 235 
(MagnaPure Compact, Roche, Monza, Italy) and genotypes were assessed through a real-time 236 
polymerase chain reaction allelic discrimination system (LightCycler 480, Roche, Monza, Italy). 237 
Investigated gene SNPs were: CYP27B1 (encoding cytochrome 27B1 enzyme responsible for VD 238 
active metabolite 1,25-VD production) rs4646536 (+2838) C>T and rs10877012 (-1260) G>T, VDR 239 
(encoding VD receptor) rs7975232 (ApaI) C>A, rs731236 (TaqI) T>C, rs10735810 (FokI) T>C, 240 
rs11568820 (Cdx2) A>G and rs1544410 (BsmI) G>A, CYP24A1 (encoding cytochrome 27B1 enzyme 241 
responsible for VD inactive metabolite 24,25-dyhydroxyvitamin D (24,25-VD) production) 242 
rs2248359 (3999) T>C, rs927650 (22776) C>T and rs2585428 (8620) A>G and finally GC (encoding VD 243 
transporter, VDBP) rs7041 A>C. 244 
All variables were tested for normality through the Shapiro-Wilk test. Normal variables were 245 
described as average and standard deviation, non-normal ones as median values and interquartile 246 
range (IQR) and categorical ones as numbers and percentages. Allele frequencies were tested for 247 
Hardy-Weinberg equilibrium. Kruskal-Wallis and Mann-Whitney tests were adopted for 248 
differences in continuous variables between genetic groups, considering statistical significance with 249 
a two-sided p-value < 0.05. Stepwise multivariate logistic regression analysis was performed 250 
including variables with a p-value below 0.2 at univariate analysis to evaluate factors are able to 251 
predict nivolumab levels < 18.7 ug/mL at 15 days. Bonferroni correction has been performed, since 252 
an adjustment made to p values is needed when several dependent or independent statistical tests 253 
are being performed simultaneously on a single data set[23].  254 
Tests are performed with IBM SPSS Statistics 25.0 for Windows (Chicago, Illinois, USA). 255 
5. Conclusions 256 
In conclusion, this is the first study showing an association between VD-related biomarkers and 257 
nivolumab plasma concentrations.  258 
In the current study, for the first time, VD deficiency seems to result in altered nivolumab clearance, 259 
as shown by different associations. Furthermore, another interesting information to highlight from 260 
these analyses is that the reduction in VD concentrations is not through antibodies.  261 
In future, aims will be to analyze VD deficiency effect on the immune system, for example 262 
evaluating the immunologic profile according to VD-related biomarkers or PD-1 or PD-L1 levels 263 
and their genetic variants.  264 
These are preliminary and limited analyses, but further studies in larger and different cohorts are 265 
needed to clarify these aspects and to improve the knowledge in the field of monoclonal antibodies 266 
treatment used in NSCLC.  267 
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